Viking Advances Obesity Pipeline, Initiates Amylin Agonist Program
Event summary
- Viking Therapeutics' Phase 3 VANQUISH trials for subcutaneous VK2735 in obesity are fully enrolled, with Phase 3 oral VK2735 trials expected to begin in 4Q26.
- The company anticipates data from a VK2735 maintenance dosing study in 3Q26.
- Viking filed an IND for its novel amylin agonist, VK3019, with Phase 1 trials planned for 2Q26.
- Viking ended March 2026 with $603 million in cash, a decrease from $706 million at the end of 2025.
The big picture
Viking is aggressively pursuing a dual-agonist strategy in the rapidly expanding obesity treatment market, aiming to offer both subcutaneous and oral formulations of VK2735. The company's focus on maintenance dosing regimens and a separate amylin agonist program indicates a broader ambition to address the complexities of long-term metabolic management. The substantial R&D spend reflects the significant investment required to advance these programs through clinical trials and regulatory review.
What we're watching
- Clinical Execution
- The rapid enrollment in the VANQUISH trials suggests strong patient interest, but the success of the Phase 3 program hinges on demonstrating statistically significant efficacy and safety compared to placebo.
- Oral Formulation
- The success of the oral VK2735 formulation will be crucial for Viking's differentiation in a competitive obesity market, and the 4Q26 initiation date is a key milestone to monitor.
- Pipeline Diversification
- The advancement of VK3019, the amylin agonist, demonstrates Viking's commitment to diversifying its pipeline beyond GLP-1/GIP dual agonists, but its clinical success remains highly uncertain.
Related topics